Biological Effects of Quercetin in COPD Phase II
Phase 2
30
about 1.7 years
40–80
1 site in PA
About this study
This trial is testing whether quercetin supplementation reduces inflammation and oxidative stress markers in people with chronic obstructive pulmonary disease (COPD). It involves a small number of participants receiving either a placebo, 1000 mg of quercetin daily, or 500 mg of quercetin daily for 638 days. The goal is to enroll approximately 30 participants.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take Placebo
- 2.Take Quercetin 1000 mg
- 3.Take Quercetin 500 MG
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Immunological Agents
oral (Oral Tablet)
Primary: C-reactive protein (CRP), and surfactant protein (SP)-D in serum
Respiratory